You are here

Non-Metal PN Scavenger/Decomposition Catalysts for Treatment of Migraine

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS107058-01
Agency Tracking Number: R41NS107058
Amount: $221,823.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA17-303
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-15
Award End Date (Contract End Date): 2019-07-31
Small Business Information
Richardson, TX 75080-2768
United States
DUNS: 079742216
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (972) 883-2385
Business Contact
Phone: (214) 793-8453
Research Institution
RICHARDSON, TX 75080-3021
United States

 Nonprofit College or University

Project SummaryAbstract
The World Health Organization ranks migraine as therd most prevalent disease worldwide andth most
disablingth most in womenmaking it the most common neurological disorderOne of the primary
reasons for the disabling nature of migraine is the poor efficacy of currently available therapeuticsLess
thanof patients achieve complete relief with acute agents such as triptans and only half of patients
achieverelief with preventative agentsOur long term goal is to identify new targets and develop
novel therapeutics against these targets to treat this common and debilitating disorderOne of the most consistent triggers for migraine is administration of a nitric oxideNOdonorApproximatelyof human migraine patients will develop an attack withinhours of NO donor
administrationDespite this observationmigraine therapeutics based on NO or its downstream
mechanisms have not yet been developedThe objective of this proposal is to test whether several
compounds under development by CerSci Therapeutics that scavenge or catalyze the decomposition of
peroxynitritePNthe reaction product of NO and superoxidehave efficacy in preclinical models of
migraineStudies over the last decade have shown that PN is an important activator sensitizer of sensory
neurons in preclinical pain models of neuropathicinflammatoryand cancer pain and agents that eliminate
PN have demonstrated efficacy in preclinical pain modelsHoweverstudies have not examined whether
targeting PN is efficacious for migraine despite the observation that the only pain state triggered by
administration of a PN producing stimulus is migraineNO donors do not directly cause other types of
painThuswe propose to test the hypothesis that CST compounds will decrease NO donorinduced migraine related behavior in preclinical models via decreased PNThe rationale for the
proposed study is that itwill demonstrate that scavenging or catalyzing the decomposition of PN is a
novel therapeutic avenue to treat migraineandwill provide the preclinical rationale for the development
of CerSci compounds that are PN scavengers decomposition catalysts to treat migraineWe will test the
hypothesis withAims using preclinical rodent modelsAimwill test the efficacy of CerSci compoundsCSTCSTand CSTagainst NO donor induced migraine behavior in rats primed
by dura mater administration of the cytokine interleukinILAimwill test the efficacy of CerSci
compoundsCSTCSTand CSTagainst NO donor induced migraine behavior in
mice primed by repetitive stressThis innovative study will for the first time investigate the efficacy of nonmetal basedorally available PN scavengers decomposition catalysts in preclinical model that mimic
conditions relevant to migraineThe significance of the proposal is that it both advances our
understanding of migraine mechanisms and has the potential to lead to novel therapeutics Project Narrative
One of the most consistent triggers for migraine is administration of a nitric oxideNOdonor and it is well
established that approximatelyof human migraineurs will develop an attack withinhours of NO donor
administrationNO readily reacts with the superoxide radical to form peroxynitritePNwhich is known to
contribute to a variety of non headache pain statesWe propose to test the efficacy of orally bioavailablenonmetal based PN scavengers and PN decomposition catalystsunder development by CerSci Therapeuticsfor
efficacy in preclinical models of migraine which may lead to the identification of a novel class of migraine

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government